JP2018522812A - カスパーゼ−６のモジュレーター - Google Patents

カスパーゼ−６のモジュレーター Download PDF

Info

Publication number
JP2018522812A
JP2018522812A JP2016552512A JP2016552512A JP2018522812A JP 2018522812 A JP2018522812 A JP 2018522812A JP 2016552512 A JP2016552512 A JP 2016552512A JP 2016552512 A JP2016552512 A JP 2016552512A JP 2018522812 A JP2018522812 A JP 2018522812A
Authority
JP
Japan
Prior art keywords
nervous system
caspase
pharmaceutical composition
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016552512A
Other languages
English (en)
Japanese (ja)
Inventor
メディ マイク カーンキシュプール，
メディ マイク カーンキシュプール，
オルガ ペティーナ，
オルガ ペティーナ，
デートレフ ゲフケン，
デートレフ ゲフケン，
ダグマー エルンホファー，
ダグマー エルンホファー，
マイケル ヘイデン，
マイケル ヘイデン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Hamburg
Original Assignee
Universitaet Hamburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Hamburg filed Critical Universitaet Hamburg
Publication of JP2018522812A publication Critical patent/JP2018522812A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/28—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having nitrogen atoms of imino groups acylated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016552512A 2014-08-05 2015-02-14 カスパーゼ−６のモジュレーター Pending JP2018522812A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033401P 2014-08-05 2014-08-05
US62/033,401 2014-08-05
PCT/IB2015/000144 WO2016020732A1 (fr) 2014-08-05 2015-02-14 Modulateurs de caspase 6

Publications (1)

Publication Number Publication Date
JP2018522812A true JP2018522812A (ja) 2018-08-16

Family

ID=55263221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016552512A Pending JP2018522812A (ja) 2014-08-05 2015-02-14 カスパーゼ−６のモジュレーター

Country Status (6)

Country Link
EP (1) EP3129027A4 (fr)
JP (1) JP2018522812A (fr)
AU (1) AU2015298491A1 (fr)
CA (1) CA2939655A1 (fr)
DE (1) DE112015001269T5 (fr)
WO (1) WO2016020732A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016144702A1 (fr) 2015-03-06 2016-09-15 Pharmakea, Inc. Inhibiteurs de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs
AU2016229268B2 (en) 2015-03-06 2020-09-10 Pharmakea, Inc. Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
CN108884049A (zh) 2016-02-09 2018-11-23 法玛克亚公司 喹啉酮赖氨酰氧化酶样2抑制剂及其用途
US10774069B2 (en) 2016-09-07 2020-09-15 Pharmakea, Inc. Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
KR102615565B1 (ko) 2016-09-07 2023-12-18 파마케아, 인크. 리실 옥시다제 유사 2 억제제의 용도
MX2022006052A (es) * 2019-11-22 2022-08-15 Univ California Inhibidores de la caspasa 6 y usos de los mismos.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69700616T2 (de) * 1996-07-02 2000-03-16 Nisshin Flour Milling Co Imid derivate
WO2008076805A2 (fr) * 2006-12-15 2008-06-26 Bristol-Myers Squibb Company Analogues d'arylpropionamide, d'arylacrylamide, d'arylpropynamide ou d'arylméthylurée en tant qu'inhibiteurs du facteur xia
US8518942B2 (en) * 2008-08-06 2013-08-27 Buck Institute For Research On Aging Caspase inhibitors and uses thereof

Also Published As

Publication number Publication date
WO2016020732A1 (fr) 2016-02-11
EP3129027A1 (fr) 2017-02-15
CA2939655A1 (fr) 2016-02-11
AU2015298491A1 (en) 2016-09-01
DE112015001269T5 (de) 2017-06-08
EP3129027A4 (fr) 2017-06-21

Similar Documents

Publication Publication Date Title
JP2018522812A (ja) カスパーゼ−６のモジュレーター
US20190298748A1 (en) App Specific Bace Inhibitors (ASBIs) And Uses Thereof
US20070213388A1 (en) Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Antagonists Useful in the Treatment of of Cognitive Disorders
EP2420235A1 (fr) Procédés et polythérapies pour traiter la maladie d'Alzheimer
IL266427B2 (en) Methods for treating Alfort syndrome using bardoxolone-methyl or its analog
US11083798B2 (en) Conjugate including peptide molecule capable of self-assembly in cell organelle and pharmaceutical composition for preventing or treating cancer including conjugate
JP6877424B2 (ja) アルギニンジンジパインの阻害剤
Parsons et al. MRZ-99030–A novel modulator of Aβ aggregation: I–mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD)
JP2002541238A (ja) 薬理活性のある化合物の細胞内送達のためのカチオン脂質として有用な、ｌ−カルニチンまたはアルカノイルｌ−カルニチンのエステル
JP6595345B2 (ja) コンフォメーション病におけるβタンパク質凝集の新規の分子モジュレーターとしての化学シャペロニン
CN116867488A (zh) 用于治疗干性老年性黄斑变性（amd）的组合物
EP2814491A1 (fr) Formulations et procédés destinés au traitement ou à la prophylaxie d'états de pré-mci et/ou de pré-alzheimer
JP2016533317A (ja) 多発性嚢胞腎の予防及び／又は治療薬
JP6314135B2 (ja) ｉｎ−ｖｉｖｏで神経変性疾患（特にアルツハイマー病）に活性なリポソーム
US20180036315A1 (en) Oxazine Derivative for Use in the Prevention of Alzheimer's Disease in at Risk Patients
JP6688503B2 (ja) 医薬用組成物
US20190192524A1 (en) Modulators of Caspase-6
WO2017222042A1 (fr) Composition pharmaceutique ophtalmique
JP2001502897A (ja) 細胞毒性ペプチド
JP2007518786A (ja) アミロイドーシスを治療するためのアミジン誘導体
US20110136774A1 (en) Anti-Apoptotic Benzodiazepine Receptor Ligand Inhibitors
JP5742029B2 (ja) コレステロ−ル搬出ペプチド
KR20230159546A (ko) 신경학적 질환을 치료하기 위한 조성물 및 방법
JP2015514742A (ja) β−アミロイドにより誘発された毒性と関連する疾患の治療における、３−（１’−アダマンチル）−１−アミノメチル−３，４−ジヒドロ−５，６−ジヒドロキシ−１Ｈ−２−ベンゾピランの使用
Adeniji Structure activity relationship (SAR) studies of a novel γ-secretase inhibitor